Tildrakizumab More Cost-Effective Than Several Competitors in Treating Moderate to Severe Psoriasis
The monoclonal antibody tildrakizumab, sold by Sun Pharma as Ilumya, is more cost-effective for treatment of moderate-to-severe psoriasis than a half dozen competitors, including top-selling adalimumab (Humira), according to data…